NHSA Unveils 2023 Work Plan for National Reimbursement Drug List Update
The National Healthcare Security Administration (NHSA) has released the “Work Plan for the National Reimbursement...
Sinocelltech Group Receives NMPA Approval for COVID-19 Vaccine Bridging Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced receiving approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase III Studies of Gallium Edotreotide Injection
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Jacobio Pharma Reports Promising Clinical Results for KRAS G12C Inhibitor Gecirasib in CRC
China-based Jacobio Pharma (HKG: 1167) has announced clinical results for its novel KRAS G12C inhibitor,...
Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
MicroPort MedBot’s Dragonfly Eye 3D Endoscopy Earns CE Mark for Intraperitoneal Procedures
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its in-house developed Dragonfly...
Merck KGaA Expands High-Purity Reagents Production in Nantong, China with EUR 70 Million Investment
Germany-based Merck KGaA (NYSE: MRK) has announced plans to expand production capacity for highly-purified reagents...
Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model
Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in...
Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment
China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...
Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis
The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co.,...
WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics
Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...
Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...
EOC Pharma’s Lusutrombopag Receives NMPA Approval for Chronic Liver Disease Treatment
China-based EOC Pharma Group has announced that its drug, lusutrombopag, has received marketing approval from...
Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...
Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...
Shanghai Junshi Biosciences Gets FDA Approval for Phase III Study of Tifcemalimab in Small-Cell Lung Cancer
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877) has announced receiving approval from the US Food...
Worg Pharmaceuticals Secures RMB 1.1 Billion in Series C Financing for Global Expansion
Worg Pharmaceuticals, a Hangzhou-based developer of allergy drugs, has reportedly raised RMB 1.1 billion (USD...
AIM Vaccine Receives NMPA Approval for mRNA Vaccine Clinical Study Targeting COVID-19 Variants
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
Sichuan Kelun-Biotech Biopharmaceutical Prices IPO at HKD 60.6 to 72.8 per Share
Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE: 002422) innovative drug development subsidiary, Sichuan Kelun-Biotech Biopharmaceutical Co.,...